Erratum: Impact of hydroxyurea on clinical events in the BABY HUG trial (Blood (2012) 120:22 (4304-4310) DOI: 10.1182/blood-2012-03-419879);Impact of hydroxyurea on clinical events in the BABY HUG trial

Blood

Volumn 120, Issue 22, 2012, Pages 4304-4310

  Thornburg, Courtney D ^a   Files, Beatrice A ^b   Luo, Zhaoyu ^c   Miller, Scott T ^d   Kalpatthi, Ram ^e   Iyer, Rathi ^f   Seaman, Phillip ^g   Lebensburger, Jeffrey ^h   Alvarez, Ofelia ⁱ   Thompson, Bruce ^c   Ware, Russell E ^j   Wang, Winfred C ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Clinical Trials & Surveys Corp   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; PLACEBO;

ACUTE CHEST SYNDROME; ANEMIA; APLASTIC CRISIS; ARTICLE; ASTHMA; BACTEREMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; CHILD; CONTROLLED STUDY; DACTYLITIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; GALLBLADDER DISEASE; GASTROENTERITIS; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTICENTER STUDY; NEUTROPENIA; OSTEOMYELITIS; OTITIS MEDIA; PAIN; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SICKLE CELL; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 84869803950     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-748764     Document Type: Erratum

References (38)

1. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
2. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010;85(8):611-613.
3. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938.
4. Thompson BW, Miller ST, Rogers ZR, et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer. 2010;54(2):250-255.
5. US Department of Health and Human Services. Code of Federal Regulations. http://www.hhs.gov/ ohrp/humansubjects/guidance/ohrpregulations. pdf. Accessed February 14, 2012.
6. Thornburg CD, Rogers ZR, Jeng MR, et al. Adherence to study medication and visits: data from the BABY HUG trial. Pediatr Blood Cancer. 2010; 54(2):260-264.
7. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86(2):776-783.
8. Pavlakis SG, Rees RC, Huang X, et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer. 2010;54(2):256-259.
9. Lebensburger JD, Miller ST, Howard TH, et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer. 2012;59(4):675-678.
10. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317-1322.
11. Fosdal MB, Wojner-Alexandrov AW. Events of hospitalization among children with sickle cell disease. J Pediatr Nurs. 2007;22(4):342-346.
12. Raphael JL, Kamdar A, Beavers MB, Mahoney DH, Mueller BU. Treatment of uncomplicated vasoocclusive crises in children with sickle cell disease in a day hospital. Pediatr Blood Cancer. 2008;51(1):82-85.
13. Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol. 2009;144(5):782-788.
14. Grosse SD, Boulet SL, Amendah DD, Oyeku SO. Administrative data sets and health services research on hemoglobinopathies: a review of the literature. Am J Prev Med. 2010;38(4 Suppl):S557-S567.
15. Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010;54(1):92-97.
16. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89(5):1787-1792.
17. Quinn CT, Shull EP, Ahmad N, Lee NJ, Rogers ZR, Buchanan GR. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood. 2007;109(1):40-45.
18. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403-408.
19. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986; 314(25):1593-1599.
20. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-1433.
21. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-182.
22. McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. J Pediatr. 2011;158(3):505-507.
23. Lebensburger JD, Howard T, Hu Y, et al. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood. 119(8): 1915-1921.
24. Lou TF, Singh M, Mackie A, Li W, Pace BS. Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med (Maywood). 2009; 234(11):1374-1382.
25. King SB. Nitric oxide production from hydroxyurea. Free Radic Biol Med. 2004;37(6):737-744.
26. Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol. 2003;38(5):421-430.
27. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005; 102(5):1661-1666.
28. Ren B, Zhang N, Yang J, Ding H. Nitric oxide-induced bacteriostasis and modification of ironsulphur proteins in Escherichia coli. Mol Microbiol. 2008;70(4):953-964.
29. Jones-Carson J, Laughlin JR, Stewart AL, Voskuil MI, Vazquez-Torres A. Nitric oxide-dependent killing of aerobic, anaerobic and persistent Burkholderia pseudomallei. Nitric Oxide. 2012;27(1):25-31.
30. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010; 115(26):5300-5311.
31. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039-2045.
32. de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006; 91(1):125-128.
33. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7):2685-2690.
34. Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009;52(5):609-615.
35. Smith WR, Scherer M. Sickle-cell pain: advances in epidemiology and etiology. Hematology Am Soc Hematol Educ Program. 2010;2010:409-415.
36. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
37. Wynn L, Miller S, Faughnan L, et al. Recruitment of infants with sickle cell anemia to a phase III trial: data from the BABY HUG study. Contemp Clin Trials. 2010;31(6):558-563.
38. Tripathi A, Jerrell JM, Stallworth JR. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Pediatr Blood Cancer. 2011;56(1):90-94.